Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031

List of Tables

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031 Report Findings & Highlights:

Global Cancer Antibody Drug Conjugates Market Opportunity: > USD 70 Billion By 2031
Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1'2025
Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2031
Number Of Approved Cancer Antibody Drug Conjugates: > 20 Antibody Drug Conjugates
Approved Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025
Approved Cancer Antibody Drug Conjugates Patent, Dosage & Price Analysis
Cancer Antibody Drug Conjugates In Clinical Trials: > 800 Drugs
Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

Need For Cancer Antibody Drug Conjugates & Why This Report?

Traditional treatments such as chemotherapy and radiation are frequently associated with high toxicity and fail to provide the specificity that would allow for sparing of normal tissue, so that patients are left with few and sometimes severe treatment options. Consequently, the demand for effective powerful and targeted cancer therapies has never been greater. In this sense, Cancer Antibody Drug Conjugates (ADCs) represent a new frontier in cancer therapy, marrying the selectivity of monoclonal antibodies with the potency of chemotherapy drugs to selectively kill cancer cells while reducing harm to normal tissue. With over 20 antibody drug conjugates approved globally, their therapeutic success is revolutionizing cancer treatment.

This report provides an analysis of the expanding cancer antibody drug conjugates market and its increasingly prominent role in modern oncology. It also records the most recent scientific advances, monitors developments through clinical pipelines, and identifies future commercial and clinical prospects, thus providing key insight for investors to navigate this high-risk, high-reward therapeutic area.

Market Opportunity, Approved Cancer Antibody Drug Conjugates Sales, Pricing, & Dosing Insight

This report provides a detailed overview of pricing, recommended dosing, and sales data for the 20 approved cancer antibody drug conjugates from 2020 to the first half of 2025. It includes both global and regional insights, along with a quarterly breakdown of sales performance. At the global level, the report outlines the total market value of the cancer antibody drug conjugates market over this period and highlights how each individual drug contributes to overall market figures.

Clinical Trials Insight Included In Report

Clinical trials are at the backbone of antibody drug conjugates development, offering insights into their utility in the treatment of a number of cancers, such as solid tumors and blood cancers. Currently, more than 800 cancer antibody drug conjugates both under investigation and approved, are being tested in clinical trials, aimed at evaluating their safety and efficacy in different cancer indications or broadening their treatable patient population. For instance, AstraZeneca and Daiichi Sankyo's TROPION trial series is currently assessing Datopotamab deruxtecan in a variety of solid tumors outside its approved uses. Genmab's RAINFOL trials are also examining the potential of Rinatabart Sesutecan in various solid tumors. These trials are critical in demonstrating how antibody drug conjugates can address high, unmet medical needs

The report contains an in-depth overview of key cancer antibody drug conjugates clinical trials, along with data on indications being tested by antibody drug conjugates, the trial sponsors, geographic regions and trial phases, providing stakeholders with an accurate picture of the development landscape at present. These observations are a valuable reminder for both commercial decision-makers and academic researchers who need to stay informed of pipeline momentum and therapeutic potential.

Technology Platforms, Collaborations & Agreements

Technology platforms are crucial to the development of antibody drug conjugates for cancer treatment, facilitating targeted delivery of cytotoxic payload to cancer cells. To illustrate this, Daiichi Sankyo's DXd platform has driven the success of antibody drug conjugates such as Enhertu and Datroway, with improved stability and controlled payload release.

Equally important are strategic partnerships, candidate acquisitions and licensing deals, that expedite development timelines, increase access to new targets, and fuel global market reach. These agreements are necessary not only to promote cancer antibody drug conjugates innovation but also to guarantee greater clinical impact and commercial success in an increasingly competitive oncology landscape.

Key Companies Involved in R&D of Cancer Antibody Drug Conjugates

Several prominent drug makers are now active at the forefront of cancer antibody drug conjugates research and development. For instance, Pfizer has enhanced its cancer treatment portfolio by acquiring Seagen, a leader in antibody drug conjugates technology, gaining access to its advanced platform and expertise in the field. AstraZeneca has also strengthened its cancer antibody drug conjugates pipeline, with candidates aiming at a range of cancers, such as ovarian and breast cancers. Emerging biotech firms like Miracogen, with its promising antibody drug conjugates MRG003, are also making waves, centering on new technologies and delivery mechanisms to improve efficacy and reduce side effects.

This report presents a comprehensive analysis of the companies leading cancer antibody drug conjugates innovation, ranging from the traditional pharmaceutical powerhouses to the new biotech upstarts, as well as the occasional technology providers. It identifies each company's strategic emphasis, pipeline development, and role in driving the future of targeted cancer treatment.

Report Highlighting Future Direction of Cancer Antibody Drug Conjugates Segment

The future of cancer antibody drug conjugates is promising, with ongoing technology improvement, new payloads, and improved linker systems. As new antibody drug conjugates continue receiving approval, like Emrelis for non-small cell lung cancer and Trastuzumab rezetecan for HER2-positive breast cancer, their potential in oncology are increasing. Besides those therapies already approved, next-generation antibody drug conjugates, including bispecific antibody drug conjugates and immune-enhancing antibody drug conjugates, are also anticipated to revolutionize cancer therapy. These treatments hold the promise of addressing tumor heterogeneity and enhancing outcome.

Providing a vision of the future, this report examines the future direction of the cancer antibody drug conjugates industry, with analysis of scientific trends, regulatory trends, and therapeutic advances. It highlights the need for biomarker-driven strategies, individualized dosing, and translational trial design in order to realize the maximum clinical potential of antibody drug conjugates in both solid tumors and hematological cancers.

1. RESEARCH METHODOLOGY

2. Introduction To Antibody Drug Conjugates

2.1 Overview
2.2 Mechanism of Antibody Drug Conjugates

3. Antibody Drug Conjugates As Cancer Targeted Therapy

3.1 Applications of Antibody Drug Conjugates in Cancer
3.2 Advantages of Antibody Drug Conjugates
3.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

4. Generations of Antibody Drug Conjugates

4.1 Antibody Drug Conjugates - Evolution
4.2 Next Generation Antibody Drug Conjugates Prospects

5. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

6. Global Cancer Antibody Drug Conjugates Market Outlook

6.1 Current Market Scenario
6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

7.1 US
7.2 China
7.3 Europe
7.4 South Korea
7.5 Australia
7.6 UK
7.7 Canada
7.8 Japan
7.9 India
7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

8.1 Lung Cancer
8.2 Breast cancer
8.3 Leukemia
8.4 Ovarian Cancer
8.5 Gastrointestinal Cancers
8.6 Lymphoma
8.7 Urothelial Carcinoma
8.8 Cervical Cancer
8.9 Head & Neck Cancer
8.10 Brain Cancer
8.11 Prostate cancer
8.12 Pancreatic Cancer
8.13 Skin cancer
8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

This Chapter Gives Comprehensive Insight On Patent, Dosage & Price Analysis For 20 Approved Cancer Antibody Drug Conjugates. We Have Mentioned Few Drug Conjugates Names For Reference, Detailed Insight Included In Sample & Report

10.1 Mylotarg
- 10.1.1 Overview, Availability & Patent Insight
- 10.1.2 Pricing & Dosage Insight
10.2 Adcetris
- 10.2.1 Overview, Availability & Patent Insight
- 10.2.2 Pricing & Dosage Insight
10.3 Kadcyla
- 10.3.1 Overview, Availability & Patent Insight
- 10.3.2 Pricing & Dosage Insight
10.4 Besponsa
- 10.4.1 Overview & Availability Insight
- 10.4.2 Pricing & Dosage Insight
10.5 Lumoxiti (Market Withdrawal In 2023)
- 10.5.1 Overview, Availability & Patent Insight
- 10.5.2 Pricing & Dosage Insight
10.6 Polivy
- 10.6.1 Overview, Availability & Patent Insight
- 10.6.2 Pricing & Dosage Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights 2020 - 2025

11.1 Adcetris
11.2 Padcev
11.3 Tivdak
11.4 Polivy
11.5 Kadcyla
11.6 Besponsa
11.7 Enhertu
11.8 Trodelvy
11.9 Zynlonta
11.10 Elahere
11.11 Blenrep
11.12 Datroway

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

12.1 Research
12.2 Preclinical
12.3 Phase I
12.4 Phase I/II
12.5 Phase II
12.6 Phase II/III
12.7 Phase III
12.8 Preregistration
12.9 Registration

13. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

15.1 Key Market Growth Drivers
15.2 Challenges For Market Growth

16. Competitive Landscape

16.1 ADC Therapeutics
16.2 Affinity Biopharma
16.3 AstraZeneca
16.4 Biocytogen
16.5 Biokin
16.6 Bristol Myers Squibb
16.7 Daiichi Sankyo
16.8 Duality Biologics
16.9 Eli Lilly
16.10 Immunogen
16.11 Innovent Biologics
16.12 LigaChem Biosciences
16.13 Merck
16.14 Pfizer
16.15 Synaffix

List of Figures

Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
Figure 3-1: Advantages of Antibody Drug Conjugates
Figure 4-1: Antibody-Drug Conjugates - Approval by Generation
Figure 4-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 6-2: Global -Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), H1'2025
Figure 6-3: Global - Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), 2024
Figure 6-4: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2024
Figure 6-5: Global - Cancer Antibody Drug Conjugate Market (US$ Million), Q1-Q4'2024
Figure 6-6: Global - Cancer Antibody Drug Conjugate Market by Drug (US$ Million), 2023
Figure 6-7: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2023
Figure 6-8: Global - Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2025 - 2031
Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), August'2025
Figure 8-1: REFRaME-L1 Phase 2 (NCT06555263) Study - Initiation & Completion Year
Figure 8-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation & Completion Year
Figure 8-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation & Completion Year
Figure 8-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation & Completion Year
Figure 8-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation & Completion Year
Figure 8-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation & Completion Year
Figure 8-7: D926QC00001 Phase 3 (NCT06112379) Study - Initiation & Completion Year
Figure 8-8: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation & Completion Year
Figure 8-9: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation & Completion Year
Figure 8-10: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation & Completion Year
Figure 8-11: CA235-0001 Phase 1 (NCT06419634) Study - Initiation & Completion Year
Figure 8-12: VNC-943-101 Phase 1 (NCT06034275) Study - Initiation & Completion Year
Figure 8-13: RAINFOL-02 Phase 3 (NCT06619236) Study - Initiation & Completion Year
Figure 8-14: RAINFOL-01 Phase 1/2 (NCT05579366) Study - Initiation & Completion Year
Figure 8-15: DS6000-109 Phase 2/3 (NCT06161025) Study - Initiation & Completion Year
Figure 8-16: FONTANA Phase 1/2 (NCT05797168) Study - Initiation & Completion Year
Figure 8-17: LOXO-FRA-24001 Phase 1 (NCT06400472) Study - Initiation & Completion Year
Figure 8-18: M24-427 Phase 1 (NCT06084481) Study - Initiation & Completion Year
Figure 8-19: CUSP06-1001 Phase 1 (NCT06234423) Study - Initiation & Completion Year
Figure 8-20: TROPION-PanTumor03 Phase 2 (NCT05489211) Study - Initiation & Completion Year
Figure 8-21: IKS014-01 Phase 1 (NCT05872295) Study - Initiation & Completion Year
Figure 8-22: D9800C00001 Phase 2 (NCT06219941) Study - Initiation & Completion Year
Figure 8-23: PROCEADE-PanTumor Phase 1/2 (NCT06710132) Study - Initiation & Completion Year
Figure 8-24: CIBI343A101 Phase 1 (NCT05458219) Study - Initiation & Completion Year
Figure 8-25: CTMX-2051-101 Phase 2 (NCT06265688) Study - Initiation & Completion Year
Figure 8-26: M21-404 Phase 1 (NCT05029882) Study - Initiation & Completion Year
Figure 8-27: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-28: ADRX-0405-001 Phase 1 (NCT06710379) Study - Initiation & Completion Year
Figure 8-29: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation & Completion Year
Figure 8-30: RG1122400 Phase 2 (NCT05453396) Study - Initiation & Completion Year
Figure 8-31: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-32: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-33: waveLINE-003 Phase 2/3 (NCT05139017) Study - Initiation & Completion Year
Figure 8-34: waveLINE-010 Phase 3 (NCT06717347) Study - Initiation & Completion Year
Figure 8-35: waveLINE-007 Phase 2 (NCT05406401) Study - Initiation & Completion Year
Figure 8-36: waveLINE-006 Phase 2 (NCT05458297) Study - Initiation & Completion Year
Figure 8-37: SUNMO Phase 3 (NCT05171647) Study - Initiation & Completion Year
Figure 8-38: NCI-2023-00999 Phase 2 (NCT05775471) Study - Initiation & Completion Year
Figure 8-39: RG1122399 Phase 2 (NCT05581589) Study - Initiation & Completion Year
Figure 8-40: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation & Completion Year
Figure 8-41: 9MW2821-2023-CP301 Phase 3 (NCT06196736) Study - Initiation & Completion Year
Figure 8-42: IDE397-001 Phase 1/2 (NCT04794699) Study - Initiation & Completion Year
Figure 8-43: ADCE-T02-01 Phase 1 (NCT06597721) Study - Initiation & Completion Year
Figure 8-44: 2000023639 Phase 2 (NCT05838521) Study - Initiation & Completion Year
Figure 8-45: DESTINY-PanTumor02 Phase 2 (NCT04482309) Study - Initiation & Completion Year
Figure 8-46: 9MW2821-2021-CP102 Phase 1/2 (NCT05216965) Study - Initiation & Completion Year
Figure 8-47: ADRX-0706-001 Phase 1 (NCT06036121) Study - Initiation & Completion Year
Figure 8-48: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
Figure 8-49: SGNDV-005 Phase 2 (NCT06003231) Study - Initiation & Completion Year
Figure 8-50: EV-202 Phase 2 (NCT04225117) Study - Initiation & Completion Year
Figure 8-51: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
Figure 8-52: SGNPDL1V-001 Phase 1 (NCT05208762) Study - Initiation & Completion Year
Figure 8-53: DB-1311-O-1001 Phase 1/2 (NCT05914116) Study - Initiation & Completion Year
Figure 8-54: IRB-43179 Phase 1/2 (NCT03510208) Study - Initiation & Completion Year
Figure 8-55: MEDOPP575 Phase 2 (NCT05865990) Study - Initiation & Completion Year
Figure 8-56: UW18043 Phase 2 (NCT03725761) Study - Initiation & Completion Year
Figure 8-57: ARTEMIS-003 Phase 2 (NCT06001255) Study - Initiation & Completion Year
Figure 8-58: NCI-2021-08857 Phase 1b/2 (NCT05011188) Study - Initiation & Completion Year
Figure 8-59: IDeate-Prostate01 Phase 3 (NCT06925737) Study - Initiation & Completion Year
Figure 8-60: IDeate-PanTumor01 Phase 1/2 (NCT04145622) Study - Initiation & Completion Year
Figure 8-61: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
Figure 8-62: TORL2307ADC-001 Phase 1 (NCT05156866) Study - Initiation & Completion Year
Figure 8-63: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-64: XNW27011-I/II-01 Phase 1/2 (NCT06792435) Study - Initiation & Completion Year
Figure 8-65: BA3021-001 Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
Figure 8-66: CP-MGC018-02 Phase 1 (NCT05293496) Study - Initiation & Completion Year
Figure 8-67: AMT-253-02 Phase 1/2 (NCT06209580) Study - Initiation & Completion Year
Figure 8-68: SGN35-033 Phase 2 (NCT04609566) Study - Initiation & Completion Year
Figure 8-69: BrUOG 413 Phase 2 (NCT05480384) Study - Initiation & Completion Year
Figure 8-70: SYSA1501-010 Phase 1/2 (NCT06577376) Study - Initiation & Completion Year
Figure 8-71: 202401158MIFD Phase 2 (NCT06329869) Study - Initiation & Completion Year
Figure 8-72: HS-20093-203 Phase 2 (NCT06112704) Study - Initiation & Completion Year
Figure 8-73: IDeate-Esophageal01 Phase 2 (NCT06644781) Study - Initiation & Completion Year
Figure 8-74: BL-B01D1-103 Phase 1 (NCT05262491) Study - Initiation & Completion Year
Figure 8-75: IPH4502-101 Phase 1 (NCT06781983) Study - Initiation & Completion Year
Figure 8-76: 9MW2821-2021-CP102 Phase 1 (NCT05216965) Study - Initiation & Completion Year
Figure 9-1: Proprietary ADC Technology - Seagen
Figure 9-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
Figure 9-3: TRAAC - Tallac Therapeutics
Figure 9-4: ATAC - Heidelberg Pharma
Figure 9-5: Tub-tag(R) & P5 - Tubulis
Figure 10-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
Figure 10-2: Mylotarg - Approval Year by Region
Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), July'2025
Figure 10-4: Adcetris - Approval Year by Region
Figure 10-5: US - Adcetris FDA Approval Year by Indication
Figure 10-6: Japan - Adcetris PMDA Approval Year by Indication
Figure 10-7: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 10-8: Adcetris - Patent Expiration by Region
Figure 10-9: Adcetris - Cost of 50 mg Supply in US (US$), July'2025
Figure 10-10: US - Kadcyla FDA Approval Year by Indication
Figure 10-11: Kadcyla - Approval Year by Region
Figure 10-12: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 10-13: Kadcyla - Cost of Supply in US & Europe (US$), July'2025
Figure 10-14: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 10-15: Besponsa - Approval Year by Region
Figure 10-16: Besponsa - Cost of 0.9 mg Supply in US & 1 mg Supply in Europe, July'2025
Figure 10-17: Lumoxiti - Orphan Designation Years
Figure 10-18: Lumoxiti - Patent Expiry Years
Figure 10-19: Lumoxiti - Cost of 1 mg Supply in US (US$), July'2025
Figure 10-20: Lumoxiti - Cost of 1 mg Supply in US & Europe (US$), July'2025
Figure 10-21: Polivy - Approval Year by Region
Figure 10-22: Polivy - Orphan Drug Designation Approval Year by Region
Figure 10-23: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 10-24: Polivy - Cost of Supply in US & Europe (US$), July'2025
Figure 10-25: Padcev - Approval Year by Region
Figure 10-26: US - Padcev FDA Approval & Patent Expiration Year
Figure 10-27: Padcev - Cost of Supply In US & Europe (US$), July'2025
Figure 10-28: Enhertu - Approval Year by Region
Figure 10-29: US - Polivy FDA Approval Year by Indication
Figure 10-30: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 10-31: Enhertu - Cost of 100 mg Supply In US & Europe (US$), July'2025
Figure 10-32: US - Trodelvy FDA Approval by Indication
Figure 10-33: Trodelvy - Approval Year by Region
Figure 10-34: Trodelvy - Patent Expiration by Region
Figure 10-35: Trodelvy - Cost of Supply In US & Europe (US$), July'2025
Figure 10-36: Blenrep - FDA & EMA Orphan Drug Designations
Figure 10-37: Blenrep - FDA & EMA Approval
Figure 10-38: Zynlonta - FDA & EMA Approval Years
Figure 10-39: Zynlonta - FDA & EMA Orphan Drug Designation Years
Figure 10-40: Zynlonta - Cost of 10 mg Supply In US & Europe (US$), July'2025
Figure 10-41: Tivdak - Cost of 40 mg Supply Europe (US$), July'2025
Figure 10-42: Ujvira - Cost of 100 mg & 160 mg Supply in India (US$), July'2025
Figure 10-43: Akalux - Sakigake Designation & PMDA Approval Year
Figure 10-44: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 10-45: Datroway - Cost of 100 mg Supply In US & Europe (US$), July'2025
Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2025
Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2025
Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2025
Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2025
Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-12: Polivy - Global Sales By Region (%), H1'2025
Figure 11-13: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-14: Polivy - Global Sales By Region (US$ Million), 2024
Figure 11-15: Polivy - Global Sales By Region (%), 2024
Figure 11-16: Polivy - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-17: Polivy - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-18: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-19: Polivy - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-20: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-21: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-22: Polivy - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-24: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-25: Polivy - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-26: Polivy - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-27: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-28: Kadcyla - Global Sales Values (US$ Million), 2020-2025
Figure 11-29: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-30: Kadcyla - Global Sales By Region (%), H1'2025
Figure 11-31: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-32: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 11-33: Kadcyla - Global Sales By Region (%), 2024
Figure 11-34: Kadcyla - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-35: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-36: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-37: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-38: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1'2025
Figure 11-39: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-40: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-41: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-42: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-43: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-44: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-45: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-46: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 11-47: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 11-48: Besponsa - Quarterly Sales by Region (%), Q1-Q4'2024
Figure 11-49: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-50: Besponsa - US Annual Sales (US$ Million), 2020-2023
Figure 11-51: Besponsa - Europe Quarterly Sales (US$ Million), 2022
Figure 11-52: Besponsa - ROW Quarterly Sales (US$ Million), 2022
Figure 11-53: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 11-54: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-55: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-56: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 11-57: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-58: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 11-59: Trodelvy - Annual Sales By Region (%), 2025
Figure 11-60: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-61: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 11-62: Trodelvy - Annual Sales By Region (%), 2024
Figure 11-63: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 11-64: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-65: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-66: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 11-67: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-68: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-69: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 11-70: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-71: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-72: Zynlonta - Global Annual Sales (US$ Million), 2021-2025
Figure 11-73: Zynlonta - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-74: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-75: Elahere - Global Annual Sales (US$ Million), 2022-2025
Figure 11-76: Elahere - Global Quarterly Sales (US$ Million), Q1-Q2'2025
Figure 11-77: Elahere - Global Quarterly Sales by Region (US$ Million), H2'2025
Figure 11-78: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-79: Blenrep - Global Annual Sales (US$ Million), 2020-2025
Figure 11-80: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4'2024
Figure 11-81: Datroway - Global Annual Sales (US$ Million), 2025
Figure 12-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2031
Figure 14-1: Antibody Drug Conjugate Combinations in Studies
Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables

Table 4-1: First Generation Antibody Drug Conjugates - Examples
Table 4-2: Second Generation Antibody Drug Conjugates - Examples
Table 4-3: Third Generation Antibody Drug Conjugates - Examples
Table 4-4: Fourth Generation Antibody Drug Conjugates - Examples
Table 5-1: Approved Antibody Drug Conjugates, July'2025
Table 6-1: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 6-2: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
Table 6-3: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
Table 6-4: Cancer Antibody Drug Conjugates - Recent IND Clearances
Table 7-1: US - Approved Cancer Antibody Drug Conjugates, May'2025
Table 7-2: China - Approved Antibody Drug Conjugates, July'2025
Table 7-3: EU - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-4: Australia - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-5: UK - Approved Antibody Drug Conjugates, July'2025
Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, July'2025
Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates, July'2025
Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates, July'2025
Table 8-3: Leukemia - Approved Antibody Drug Conjugates, July'2025
Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
Table 8-9: Head & Neck Cancer - Approved Antibody Drug Conjugates
Table 10-1: Adcetris - Recommended Dosage
Table 10-2: Datroway - Premedication and Concomitant Medications
Table 10-3: Datroway - Recommended Dosage Reductions for Adverse Reactions
Table 10-4: Emrelis: Recommended Dose Reductions
Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031

Description

Table of Contents

List of Tables

Table of Contents

1. RESEARCH METHODOLOGY

2. Introduction To Antibody Drug Conjugates

3. Antibody Drug Conjugates As Cancer Targeted Therapy

4. Generations of Antibody Drug Conjugates

5. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

6. Global Cancer Antibody Drug Conjugates Market Outlook

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

11. Approved Cancer Antibody Drug Conjugates - Sales Insights 2020 - 2025

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

13. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

16. Competitive Landscape

List of Figures

List of Tables